# Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer
ER-positive breast cancer is one of the clearest dormancy settings in oncology.
Late relapse can happen many years after diagnosis.
That pattern fits with residual cells staying alive, but quiet, in places such as bone marrow.
### Why ER-positive disease is different
ER-positive breast cancer has a long tail of recurrence risk.
That risk can continue for decades.
This is one reason dormancy matters so much in this subtype.
Researchers increasingly interpret this pattern as evidence of **dormant disseminated tumour cells** that survive initial treatment, remain scan-invisible, and later reactivate.
### How endocrine therapy fits the dormancy picture
Endocrine therapy lowers estrogen signalling.
That includes **tamoxifen**, **aromatase inhibitors**, and **ovarian suppression** such as **goserelin (Zoladex)**.
These treatments can shrink active disease.
They can also help push some residual ER-positive cells into a low-growth or dormant state.
That helps explain why some patients experience long periods of **stable disease** even when every last cell is probably not gone.
Some recent reviews now describe adjuvant endocrine therapy as one practical strategy for **maintaining cellular dormancy** in ER-positive disease.
### Why relapse can still happen later
Dormancy is not the same as cure.
Estrogen deprivation affects more than the tumour cell.
It can also reshape the surrounding niche.
Experimental work suggests that bone-marrow stromal injury, stromal senescence, oxidative stress, hypoxic stress, and inflammatory cytokines such as **IL-6** and **IL-8** may help reawaken dormant ER-positive cells.
This offers one plausible explanation for a hard clinical pattern:
* endocrine therapy helps hold disease quiet for years
* residual cells remain too small to detect
* a later biological shift allows regrowth
> *"Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames"*\
> [**Respiratory viral infections awaken metastatic breast cancer cells in lung**](https://pubmed.ncbi.nlm.nih.gov/40739350/)
### Why this matters when disease looks small or stable
This is where dormancy thinking becomes practical.
A tiny stable focus is not always a simple "kill it now" problem.
Sometimes the more useful question is whether the current strategy is helping keep residual ER-positive cells suppressed.
That does **not** mean ignoring progression.
It means balancing eradication, long-term control, quality of life, and the risk of triggering a more inflammatory or disruptive environment.
### Related dormancy pages
* [Beyond Kill It All](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/beyond-kill-it-all.md)
* [Inflammation, Stress and Dormancy Escape](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/inflammation-stress-and-dormancy-escape.md)
* [Treatment Strategies](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/treatment-strategies.md)
* [Autophagy and Senescence in Antiestrogen Resistance](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance.md)
### Bottom line
In ER-positive breast cancer, endocrine therapy can sometimes do more than shrink visible disease.
It may also help hold residual cells in dormancy.
That helps explain both long periods of stability and the possibility of very late relapse.
### Key references
Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma\
Breast cancer dormancy: need for clinically relevant models to address late recurrence\
Dormancy and Recurrence in Breast Cancer Bone Metastasis\
### Navigate this section
* [Overview](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/overview.md)
* [What Dormant Cancer Cells Are](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/what-dormant-cancer-cells-are.md)
* [Beyond Kill It All](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/beyond-kill-it-all.md)
* [Inflammation, Stress and Dormancy Escape](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/inflammation-stress-and-dormancy-escape.md)
* [Treatment Strategies](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/treatment-strategies.md)
* [Dormancy-Focused Agents and Adjuncts](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/dormancy-focused-agents-and-adjuncts.md)
* [Questions for Your Oncology Team](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/questions-for-your-oncology-team.md)
* [Dormancy Glossary](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/dormancy-glossary.md)
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/endocrine-therapy-stable-disease-and-dormancy-in-er-positive-breast-cancer.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.